Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (January 2016)
35 slides from Relmada Therapeutics's investor presentation, Jan 13, 2016
Slide 1: Relmada Therapeutics: Innovations in Pain Medicine
ef RELMADA THERAPEUTICS Innovations in Pain Medicine™ January 2016 Ticker Symbol OTCQB:RLMD
Slide 2: Forward Looking Statements
gg, A ea ot RELMADA Forward Looking Statements Certain statements contained in this presentation or in other documents of Relmada Therapeutics (the Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward- looking
Slide 3: Company Highlights
gg, A ea ev? RELMADA Company Highlights e Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain e Three products combine proven drug candidates with novel delivery methods to create new drugs with new indica
Slide 4: Experienced Senior Management
RELMADA Experienced Senior Management An impressive track record developing and commercializing successful drugs Sergio Traversa, PharmD Chief Executive Officer Eli Lilly, Johnson & Johnson, ING Barings, Mehta & Isaly, Merlin BioMed, Rx Capital Richard Mangano, Ph.D. Chief Scientific Officer Hoffman
Slide 5: Scientific Advisors
ot aaa Scientific Advisors Internationally recognized expertise from world-class scientific advisors Memorial loan Kettering Imperial College a JOHNS HOPKINS Cancer Center.- London MEDICINE Gavrit Pasternak, MD, PhD Andrew Rice, MD, FRCA Eric C. Strain, MD eve ue ry Oe aly rete tar Reeteh asta Pere
Slide 6: Pain: Largest U.S. Public Health Crisis
Pain: Largest U.S. Public Health Crisis 328 Million Prescriptions and $13 Billion in Sales® Prevalence 100M: Persistent Pain Annual Healthcare & Productivity Cost: $560-630 Billion’ 80M? © cardiovascular Disease Annual Healthcare & Productivity Cost: $309 Billion’ 29M® © cancer Annual Healthcare & P
Slide 7: Unsatisfied Market
RELMADA Unsatisfied Market Better pain drugs are needed of chronic pain patients currently using opioids say they have “only a little” or “no control” over their pain. | 23% of patients report that opioids are “very effective” in controlling chronic pain. Source: Voice of Chronic Pain A National Stu
Slide 8: Portfolio Covers Entire Chronic Pain Spectrum
e? RELMADA Portfolio Covers Entire Chronic Pain Spectrum Pain Intensity Products in Market 2014 Sales ($M) Relmada Product Candidates Kadian®** Avinza@™* iv} LevoCap ER REL-A015 Severe Opanae™ Nucynta@** OxyContin® , BuTab Vicodin®* REL-1028 Ultrame* Moderate BuTrans® Suboxone® d-Methadone REL-1017
Slide 9: Robust Product Portfolio
Robust Product Portfolio Significant value creation possible in 12-24 months due to accelerated development timelines d-Methadone Novel NIDA antagonist or REL-1017 __ the teatment of neuropathic pain Extended release, abuse Beucs eee resistant form of broad ‘spectrum opioid levorphanol MepiGel __Tep
Slide 10: d-Methadone (REL-1017, dextromethadone)
d-Methadone (REL-1017, dextromethadone) Novel NMDA antagonist for the treatment of neuropathic pain
Slide 11: d-Methadone — A New Drug for the Treatment of NP
RELMADA d-Methadone — A New Drug for the Treatment of NP Neuropathic pain represents a multi-billion market opportunity ready for a new effective entry + d-Methadone is a novel drug = Potential new treatment for >6 million patients suffering from the most commonly studied chronic neuropathic pain su
Slide 12: NMDA Receptor — Validated Target in Neuropathic Pain
et RELMADA NMDA Receptor — Validated Target in Neuropathic Pain Safety of some antagonists, such as ketamine, precludes clinical use one © O polyamine ‘A051, te receptor per is blocked by Nag2* whieh mst be removed by sight ‘membrane a alow cation conductance. Snding ses fer glutamate, the endogenou
Slide 13: d-Methadone — Single/Multiple Ascending Dose Studies
gg, A ea e? RELMADA d-Methadone — Single/Multiple Ascending Dose Studies * SAD study conducted in 42 healthy, opioid naive subjects; MAD study conducted in 24 subjects * The objective was to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of oral single and multiple ascendin
Slide 14: d-Methadone Next Steps
e? RELMADA d-Methadone Next Steps Multiple development milestone potential in next 12-24 months 2015 2016* 2017* Completed Phase I single dose study in 42 subjects e | multi dose study in File IND and start Phase II proof of concept study in PHN Planned Phase Il interim analysis. Complete Phase Il C
Slide 15: BuTab (REL-1028)
BuTab (REL-1028) First oral tablet form of buprenorphine for treating both pain and addiction
Slide 16: BuTab — Benefits, Advantages, Features
RELMADA BuTab — Benefits, Advantages, Features The first form of buprenorphine in a tablet for use in pain and treating addiction Buprenorphine is a partial opioid agonist with two indications: addiction and pain No “traditional oral tablet” available for buprenorphine — Historically suffers from po
Slide 17: Buprenorphine Landscape
e? RELMADA Buprenorphine Landscape Nearly a $2 billion annual market for pain and opioid addiction indications Pain Therapy Opioid Addiction ($500 Million Market Opportunity’) (~$1.8 Billion Market?) ‘Sublingual Film/Tablet & Buccal Patch ‘Sublingual Film/Tablet & Buccal Patch Company Status Company
Slide 18: Positive Proof-of-Concept PK Study
RELMADA % Buprenorphine Bioavailal Positive Proof-of-Concept PK Study Absolute Bioavailability of BuTab Relative to Intravenous Administration Exceeded Published Data with Non-Modified Buprenorphine BuTab Formulation C BuTab Formulation B Hi = Mean BuTab Formulation A. - ange (max) Sublingual Tablet
Slide 19: BuTab PK Modeling of Multiple Dose Administration
BuTab PK Modeling of Multiple Dose Administration Predicted steady state plasma levels fall within the therapeutic range of approved buprenorphine products for treatment of chronic pain 1400.0 1200.0 — Z 10000 2 = 8000 8 i = g Hy 8 & ° 4 8 2 16 20 24 Time (h) Note: Using single dose PK profile and.
Slide 20: BuTab Next Steps
et RELMADA BuTab Next Steps Multiple development milestone potential in next 12-24 months 2015 2016* * Future milestones subject to capital 2017* 20
Slide 21: LevoCap ER (REL-1015)
LevoCap ER (REL-1015) Extended release, abuse resistant form of broad spectrum opioid levorphanol
Slide 22: LevoCap ER - Benefits, Advantages, Features
ot RELMADA LevoCap ER - Benefits, Advantages, Features LevoCap ER will compete in the $8.5 billion opioid market if approved + LevoCap ER is an extended release, abuse deterrent, patent protected formulation of levorphanol + Levorphanol is a unique, broad spectrum opioid with additional “non-opioid”
Slide 23: How LevoCap ER Works
How LevoCap ER Works Levorphanol’s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Ascending Pathways Works to inhibit pain by binding to opioid receptors Non-Opioid Mechanism Descen
Slide 24: Levorphanol's Broad Spectrum Activity
RELMADA Levorphanol’s Broad Spectrum Activity Levorphanol’s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Traditional Mu Opioid Receptors Delta Opioid Receptor Kappa Opioid Recepto
Slide 25: LevoCap ER Next Steps
LevoCap ER Next Steps Multiple development milestone potential in next 12-24 months 2015 2016* 2017* ‘Obtained regulatory approval from Health Canada to start clinical trial Completed PK work Conduct Type B meeting with FDA art Phase Ill tential partnership * Future milestones subject to capital 25
Slide 26: MepiGel (REL-1021)
MepiGel (REL-1021) Topical gel dosage form of the local anesthetic mepivacaine for the treatment of neuropathic pain eo RELMAD
Slide 27: MepiGel — Benefits, Advantages, Features
gg, A ea e? RELMADA MepiGel — Benefits, Advantages, Features MepiGel will compete with Lidoderm® patch and its $948 million in peak sales if approved + MepiGel is the first topical gel dosage form of local anesthetic mepivacaine, which has intrinsic vasoconstrictor attributes — Reduces rate at which
Slide 28: MepiGel Next Steps
MepiGel Next Steps Multiple development milestone potential in next 12-24 Completed formulation work / Selected formulation Toxicology File Clinical Trial Application (CTA) Complete Phase | in ~20 patients Plan for Phase Il * Future milestones subject to capital months 2015 2016* 2017* 28
Slide 29: Milestones & Commercial Opportunity
MILESTONES & COMMERCIAL OPPORTUNITY RELMADA
Slide 30: Near-term Value Drivers
RELMADA Near-term Value Drivers Multiple development milestone potential in next 12-24 months Ee PET CPE ERE “Completed Phase | ¥ Completed Phase | + File IND and start Phase Il proof of concept study in| + Complete Phase II RED single dose study in multidose study in | | PHN + End of Phase Il 5 42
Slide 31: Recent Deal Flow and Financing
RELMADA Recent Deal Flow and Financing Activity fits well with Relmada's pipeline NMDA antagonists Opioids Jun 2018 ~ Spinifex acquired by Novarts for~| '$700 milion; angiotensin type 2 receptor ‘antagonist “Jul 2015 — Nautex Jan 2016 ~ Depomed ‘acquired by Allergan for + acquires U.S. nights to '$5
Slide 32: Industry Peer Group
ot RELMADA Market Company | Symbol | coe cna) Egalet EGLT ~$263 Acura ACUR ~$27 Biodelivery E eet BDSI $269 Collegium = COLL “$542 Durect DRRX ~$269 Intelli- pharmaceutics (PC! ED Pernix Px “$176 KemPharm KMPH. ~$281 Industry Peer Group Business Summary Have abuse deterrent technology. Market Oxado
Slide 33: Financial Snapshot
RELMADA Financial Snapshot Ticker Cash & Equivalents (as of 9/30/15) Operating Expenses (three months ended 9/30/15) Common Shares Outstanding (as of 11/6/15) 52-Week Stock Price Range RLMD (oTcae) ~$19.1 million $4.6 million ~11.5 million $2.00 to $19.90 33
Slide 34: Company Highlights
gg, A ea ev? RELMADA Company Highlights e Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain e Three products combine proven drug candidates with novel delivery methods to create new drugs with new indica
Slide 35: Relmada Therapeutics contact details
ef RELMADA THERAPEUTICS Innovations in Pain Medicine™ 275 Madison Avenue, Suite 702 New York, NY 10016 www.relmada.com Email: info@relmada.com Ticker Symbol OTCQB:RLMD
Relmada Therapeutics — Investor Presentation (January 2016) on 6ix